| 3.7759 -0.004 (-0.11%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.04 | 1-year : | 5.53 |
| Resists | First : | 4.32 | Second : | 4.73 |
| Pivot price | 4.23 |
|||
| Supports | First : | 3.65 | Second : | 3.03 |
| MAs | MA(5) : | 3.94 |
MA(20) : | 4.22 |
| MA(100) : | 3.85  |
MA(250) : | 3.79 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 3.5 |
D(3) : | 15.7 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 5.96 | Low : | 2.54 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ XBIO ] has closed above bottom band by 15.0%. Bollinger Bands are 54% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.98 - 4 | 4 - 4.02 |
| Low: | 3.71 - 3.73 | 3.73 - 3.74 |
| Close: | 3.75 - 3.78 | 3.78 - 3.8 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Fri, 22 Mar 2024
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results - Miami Herald
Wed, 18 Oct 2023
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held ... - Kansas City Star
Fri, 12 May 2023
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - Yahoo Finance
Wed, 03 May 2023
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison - AccessWire
Tue, 12 Oct 2021
The 10 Best Safe Stocks To Buy For Portfolio Stability In %currentmonth% %currentyear%! - The Stock Dork
Tue, 16 Jun 2020
Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia ... - AccessWire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 19 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 2 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -2.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.36 |
| Profit Margin | -162.8 % |
| Operating Margin | -186.9 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -35.3 % |
| Qtrly Rev. Growth | 38 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.64 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -1.4 |
| PEG Ratio | 0 |
| Price to Book value | 0.59 |
| Price to Sales | 2.28 |
| Price to Cash Flow | -1.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|